GSK2578215A is primarily utilized in research settings to study its effects on neurological pathways, particularly those involved in Parkinson's disease. It acts as a potent and selective inhibitor of LRRK2 kinase, a protein implicated in the pathogenesis of familial and sporadic forms of the disease. By inhibiting LRRK2, this compound helps researchers understand the role of this kinase in neurodegeneration and assess its potential as a therapeutic target. It is also used in preclinical studies to evaluate its efficacy and safety in modulating LRRK2 activity, providing insights for developing novel treatments for Parkinson's and related disorders.